Atrophic Acne Scars
Conditions
Keywords
Atrophic Acne Scars, ELAPR002f injectable gel
Brief summary
Visit the study website https://dawnacnescarstudy.com/ACT for more information. Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars. ELAPR002f Injectable Gel is an investigational device being developed for the treatment of facial atrophic acne scars. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 156 adult participants with moderate to severe atrophic acne scarring on both cheeks will be enrolled in the study in approximately 12 sites in Germany and Canada. Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Interventions
DEVICEELAPR002f Injectable Gel
Intradermal Injections
OTHERSaline Active Control
Intradermal Injections
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants in general good health, with no active COVID-19 infection, and seeking improvement of atrophic acne scars. * Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan ASIS) on each cheek based on Evaluating Investigator's live assessment (both cheeks must qualify but do not need to have the same score) at the first screening visit. * At least 5 rolling or boxcar-type acne scars in total within the predefined assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator.
Exclusion criteria
* The participant has clinically significant acne on the face. * Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face. * The participant presents with predominantly ice pick scars. * History of keloid scar formation, hypertrophic scarring and/or post inflammatory hyperpigmentation or hypopigmentation. * History of granulomatous or connective tissue disease. * Diagnosed autoimmune disease (eg, Type 1 diabetes, rheumatoid arthritis, scleroderma, vitiligo). * Diagnosed history of lung disease. * Known hypersensitivity to the constituents of the device. * Visual acuity of 20/100 or worse or abnormal confrontational visual fields or ocular motility.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving "Responder" Status Based on the Allergan Acne Scar Improvement Scale (ASIS) | Baseline to Day 181 | A "responder" is a participant who achieves at least a 1-grade improvement on both cheeks based on the ASIS, as assessed by the EI. The ASIS is a 5-grade scale used to assess acne scar improvement ranging from 1=Almost None to 5=Severe. Each side of the face is scored separately. |
| Number of Participants with Adverse Events | Up to Day 420 | An AE is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical device. This definition includes events related to the investigational medical device or comparator and events related to the procedures involved. |
| Number of Participants with Presence of Binding Antibodies | Up to Day 420 | Presence of binding antibodies |
| Number of Participants with Injection Site Responses (ISRs) and Systemic Responses | Up to Day 420 | Incidence of ISRs/systemic responses as recorded by e-diary for up to 30 consecutive days after each of the 3 treatment sessions starting on the day of injection. ISRs are defined as redness, pain after injection, tenderness to touch, firmness, swelling, lumps/bumps, bruising, itching and discoloration (not redness or bruising). |
| Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters | Up to Day 420 | Vital sign parameters include body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance. |
| Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters | Up to Day 420 | Clinical laboratory parameters include tests of hematology, chemistry, and urinalysis. The investigator will assess the results for clinical significance. |
| Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements | Up to Day 420 | Physical measurements include weight and BMI. The investigator will assess the results for clinical significance. |
| Change from Baseline Procedure Pain | Up to Day 61 | Participants will assess procedure pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) after each of the 3 treatment sessions. |
| Number of Participants with a Positive Skin Test | Up to Day 30 | Participants will undergo a skin test in the volar area of the forearm to test for hypersensitivity. |
| Number of Participants with Visual Disturbance Symptoms Associated with Vascular Occlusion | Up to Day 420 | Number of participants with any acute cognitive changes or any change in confrontational visual fields, ocular motility, or a worsening (1-line change or more) on the Snellen visual acuity assessment, |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline on the Overall Score of ACNE-Q Acne Scars Scale | Up to Day 420 | The ACNE-Q Acne Scars scale includes 10 questions that ask how much the participant is bothered by their acne scars on a 4-point scale ranging from 1=Not at all to 4=Very Much. |
| Change from Baseline on the Overall Score of ACNE-Q - Appearance-Related Distress Scale | Up to Day 420 | ACNE-Q - Appearance-Related Distress scale includes 10 questions that ask about how the participants describe themselves on a 4-point scale ranging from 1=Never to 4=Always. |
| Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin Scale | Up to Day 420 | FACE-Q Satisfaction With Skin scale questionnaire includes 12 questions that ask how much the participants are satisfied or dissatisfied with their facial skin on a 4-point scale ranging from 1=Very Dissatisfied to 4=Very Satisfied. |
| Percentage of Participants Achieving "Responder" Status Based on the ASIS | Up to Day 420 | A "responder" is a participant who achieves at least a 1-grade improvement on both cheeks based on the ASIS, as assessed by the EI. The ASIS is a 5-grade scale used to assess acne scar improvement ranging from 1=Almost None to 5=Severe. Each side of the face is scored separately. |
Countries
Canada, Germany
Contacts
STUDY_DIRECTORABBVIE INC.
AbbVie
Outcome results
None listed